Human genetic study links immune proteins to multiple diseases
Genetic data linked 129 of 151 immune-related proteins to at least one of 50 diseases or 14 health measures, highlighting potential drug targets.
Our read
Mechanisms- Studied:
- Mendelian randomization in participants in plasma protein and disease GWAS
- What changed:
- Associated immune proteins were linked to a median of 8 diseases or biomarkers each
- The catch:
- Overlapping outcomes can count manifestations of the same disease as links to multiple diseases
- In the record:
- The 922nd paper on APOE with results in people; 3,908 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Human blood-protein data from eight large genetic studies were used in a Mendelian randomization analysis of 151 immune-related proteins. This approach used inherited genetic differences linked to protein levels to assess associations with 50 diseases and 14 health measures.
Many proteins were linked to multiple outcomes. Links were common for conditions including type 2 diabetes and Parkinson’s disease. The researchers identified seven protein communities connected to biological processes. Further analyses identified 33 associations supported by independent data and evidence that the protein and outcome associations shared an underlying genetic variant. The authors highlighted proteins that drugs already target, or might target, as opportunities to explore existing medicines for other diseases and develop new ones.
Why it matters
Age-related conditions such as Parkinson’s disease raise questions about shared biological pathways. The authors propose that immune-protein targets could offer opportunities to investigate medicines across disease boundaries.
Caveats
Genetic variants could affect disease through routes other than the protein being studied, a source of bias the researchers tried to limit. Independent replication data were available for 567 of the 1,213 associations that passed the study’s statistical threshold.
The paper
The immunoproteome and multimorbidity: A Mendelian randomization study
University College London; Amsterdam UMC Location University of Amsterdam
Science Advances, May 20, 2026, Open access



Comments
Be the first to comment.